Clinical Trial: Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional
Official Title: A Single Center Pilot Trial of Rituximab in the Treatment of Fibrillary Glomerulonephritis
Brief Summary: Will use of Rituximab reduce proteinuria over a 12 month period and will there be preservation of kidney function with the use of this study drug?
Detailed Summary:
This is a Phase II, open-label study to determine if the use of Rituximab reduces proteinuria over a 12 month period and is there preservation of kidney function with the use of this study drug.
Aim 1) Preservation of kidney function at 12 months as defined by stable or improved 24 hour creatinine clearance.
Aim 2) Reduction in proteinuria at 12 months & improved quality of life at 12 months validated by questionnaire.
Sponsor: Mayo Clinic
Current Primary Outcome: Preservation of kidney function [ Time Frame: 12 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Reduction in proteinuria [ Time Frame: 12 months ]
Original Secondary Outcome: Same as current
Information By: Mayo Clinic
Dates:
Date Received: July 21, 2014
Date Started: November 2014
Date Completion: April 2017
Last Updated: April 27, 2016
Last Verified: April 2016